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Objectives: To evaluate the detection rate of
prostate cancer (PCa) in patients who under-
went to “in bore” Magnetic Resonance Imaging -guided prostate
(MRI-GB) biopsy compared to the standard transrectal ultra-
sound guided prostate biopsy (TRUS-GB).
Materials and methods: Between January 2017 and March 2015
a cohort of 39 consecutive patients was prospectively enrolled. All
the patients underwent an "in-bore" guided MRI prostatic biopsy
and subsequently ultrasound-guided standard prostate biopsy. 
Results: Median age of patients was 65.5 years (SD ± 6.6), medi-
an total PSA serum level was 6.6 ng/ml (SD ± 4.1), median
prostate total volume was 51.1 cc (SD ± 26.7). Thirty of 39
(76.9%) were biopsy-naïve patients while 7/39 (17.9%) had at
least one previous negative random TRUS-GB; 2/39 (5.1%)
patients were already diagnosed as PCa and were on active sur-
veillance. In 18/39 (53.8%) men Pca was diagnosed; as regards
the MRI-GB results related to the PI-RADS score, biopsies of PI-
RADS 3 lesions were positive in 5/18 cases (27.8%), while the
number of positive cases of PI-RADS 4 and 5 lesions was 7/11
(63.6%) and 6/10 (60%)respectively. At the histological examina-
tion, 4/39 (10.3%) had a PCa ISUP grade group 1, 11/39 (28.2%)
had a ISUP 2, 6/39(15.4%) had a ISUP grade group 3 and 2/39
(5.1%) had a ISUP 4-5. 
Conclusions: MRI-GB represents a promising technique that may
offer some of advantages compared to standard systematic TRUS-
GB. Our preliminary experience in MRI-GB resulted safe and
feasible and represents a viable procedure for the diagnosis and
characterization of PCa.
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centage of cases (25-30%), PCa may arise from the ante-
rior part of the gland (anterior horn of peripheral gland,
central/transitional zones and fibromuscular stroma). For
these reasons, “random” TRUS-GB has a false negative rate
of up to 40-50% (5, 6) and clinically significant tumors
can often be undetected, especially in larger glands. A
higher number of cores can improve the rate of tumors
identified but, at the same time, increases the risk of diag-
nosis of indolent diseases: an aggressive management of
these overdiagnosed cases will inevitably lead to an
overtreatment, thereby negatively affecting the patients'
quality of life. Magnetic Resonance Imaging (MRI) is a tool
of growing importance in PCa diagnosis; furthermore,
with the introduction of multiparametric MRI (mpMRI)
the accuracy for characterization of prostate lesion is sig-
nificantly improved. mpMRI, performed before the biop-
sy, can improve the detection of occult tumors in the
areas of prostate generally undersampled during random
TRUS-GB. A growing body of evidences suggest that an
accurate tumor identification and sampling can improve
risk classification and should reduce false-negative rates
and the necessity of repeat biopsies both in biopsy-naïve
patients and in patients with prior negative-biopsy (7-
10). However, the increasingly widespread use of the
mpMRI for the detection of clinically significant PCa has
involved the need for targeted biopsy reducing the sam-
pling in non-suspicious areas. The techniques for target-
ed biopsy include visual estimation TRUS-GB, software
co-registered MRI ultrasound fusion and in-bore MRI-
guided biopsy (MRI-GB); the latter provides the great
advantage of direct visualization of the targeted lesion
with the same system. Thus, the aim this study was to
evaluate the detection rate of prostate cancer in patients
underwent to “in bore” MRI-guided prostate biopsy com-
pared to the standard ultrasound guided prostate biopsy;
for secondary endpoint we evaluated the morbility and
the complications of both procedures.
MATERIALS AND METHODS
Study methodology and population
Between January 2017 and March 2015 a cohort of 39
DOI: 10.4081/aiua.2019.2.87
INTRODUCTION
Prostate Cancer (PCa) represents the most common neo-
plasm diagnosed in men and the second cause of death
after lung cancer (1). Digital rectal examination, serum
PSA assay and ultrasound-guided biopsy (TRUS-GB) are
common methods for prostate cancer diagnosis (2)
although not devoid of some limitations and questionable
validity. In fact, during prostate ultrasound, the yield of
cancer detection remains very low, ranging between 20
and 30% for patients with a serum PSA value between 2
and 4 ng/ml (3, 4); moreover, in a non-negligible per-
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consecutive patients was prospectively enrolled. The study
was conducted with the approval of the institutional
review board and all the procedures and reporting were in
accordance with the Helsinki protocol. Patients were
informed and a subsequent written consent was acquired.
All patients had a suspicion for PCa – raised Prostate
Specific Antigen (PSA) serum level and/or abnormal digital
rectal examination (DRE) – and showed at the mp-MRI
previously conducted in our institution at least one suspi-
cious area where the presence of a clinically significant
PCa was defined equivocal/likely/highly likely, correspon-
ding to a PI-RADS (Prostate Imaging Reporting and Data
System) score ≥ 3 according to the European Society of
Urogenital Radiology (ESUR) guidelines (17). Patients with
any usual contraindications for MRI (eg. metallic implants
and/or cardiac pacemakers) were excluded from the
study. All patients underwent a "in-bore" guided MRI pro-
static biopsy and subsequently ultrasound-guided stan-
dard prostate biopsy; the urologist who performed the
ultrasound-guided prostatic biopsy was always the same
and was not aware of the result of mpMRI. 
MRI examination and analysis
All the MRI examinations were performed with a 32 chan-
nels 1.5 T whole body scanner (Achieva XR; Philips Medical
Systems, Best, Netherlands) with a 32-channels phased-
array surface coil without endorectal coil. After local three-
plane acquisition, required for the correct positioning of
the sequences, the morphological and functional studies
were carried out. Morphological study of the prostate
gland were obtained with Turbo Spin Echo (TSE) T2-
weighted sequences (TE 100 msec, TR 4074 msec, Slice
Thickness 3 mm, Slice Spacing 0.3 mm, Field of View – FOV
180 x 180 mm and matrix size 276 x 205) in the sagittal,
axial and coronal planes, including seminal vesicles and
the entire prostate gland. For the functional study, DWI,
DCE-MRI and MRS acquisition were performed. The DWI
acquisition was carried out in the axial plane, using a sin-
gle-shot echo-planar imaging (SSEPI) sequence, with three
b-values (0, 600 and 1500 s/mm2), slice thickness of 3
mm, FOV 180 x 180 mm and matrix size 80 x 71. The
DCE-MRI was obtained using three-dimensional (3D)
T1W High Resolution Isotropic Volume Examination
(THRIVE) sequence during the intravenous injection of a
contrast bolus of 0,1 mmol per kilogram of body weight
of Meglumine gadobenate (Multihance, Bracco Diagnostics,
Milan, Italy), at flow rate of 3,5 ml/sec followed by 15 ml
of saline solution. 
Conduct of the “in-bore” MRI-guided biopsy
The biopsies were performed on a different day from the
diagnostic mpMRI study (within 2-4 weeks) by a single
urologist. All patients received oral antibiotic prophylac-
tic therapy 2 days before the maneuver; biopsies were
performed transrectally with the patient prone on a 1.5
T MR scanner (Achieva XR; Philips Medical Systems, Best,
Netherlands) using a 18-G automatic core-needle, a tita-
nium double-shot biopsy gun, a Gadolinium-filled nee-
dle-guide, a non-magnetic portable biopsy device
(DynaTRIM, Invivo, Gainesville, FL) and a dedicated soft-
ware package for device tracking and target localization
(DynaCAD, Invivo, Gainesville, FL). Before biopsy, DRE
was performed in order to evaluate any potential
anatomic or pathologic condition that could hinder tran-
srectal biopsy and to approximate the position of the
gland. The needle sleeve is also a marker for software
localization; after the sleeve was assembled on the arm of
the biopsy device, fixed on the tabletop of the magnet,
and inserted into the rectum, the patient was positioned
into the scanner. T2w images in the axial and sagittal
direction were obtained for visualization of the prostate
and identification of the suspicious lesion; simultaneous-
ly, the Gadolinium-filled needle guide was properly
identified and marked for subsequent track calibration:
oblique axial T2w images were aligned with the needle
guide in  order to allow software registration showing
three-dimensional adjustments required to align the
track of the biopsy needle through the needle guide and
the target lesion. After manual calibration adjustments
on the arm of the biopsy device attached to the needle
guide, sagittal T2w images in parallel with the long axis
were obtained in order to confirm the correct position
and the proper direction of the needle guide to the tar-
get; reconfirmation of the needle track were repeated
until proper alignment was obtained. Once the patient
was taken from the scanner, biopsy was performed with
a median of 2 (range 1-2) cores taken from each target
lesion. If targeting was not certain, due to lesion size or
subjective judgement of the operator, subsequent axial
and sagittal T2w images with the needle in place were
obtained to detect needle position and be able to make
adjustments for the next core. Total table time was
appreciatively 45 to 70 minutes per patient. After the
procedure, patients were observed for 1 hour and were
re-evaluated by outpatient visit after 7-10 days in order
to record any potential complication. Specimens were
processed by routine hystopathological fixation with for-
malin solution and evaluated by a single dedicated uro-
pathologist with 20 years of experience. 
Conduct of ultrasound guided prostate biopsy
The standard biopsy was performed by transrectal
approach; the examination was tipically 12 cores collect-
ed in a sextant template of biopsies from the medial and
lateral area of the apical, mid and the base of prostate, on
the left and right lobe. During the TRUS guided biopsy
the mpMRI data target was not available. Total table time
was appreciatively 15 to 30 minutes per patient. After
the procedure, patients were observed for 1 hour and
were re-evaluated by outpatient visit after 7-10 days in
order to record any potential complication. antibiotic
prophylaxis was continued by patients for seven days
after the procedure. Specimens were processed by rou-
tine hystopathological fixation with formalin solution
and evaluated by a single dedicated uro-pathologist with
20 years of experience. 
Statistical analysis
Simple descriptive statistical techniques were used to ana-
lyze data, in particular median with interquartile range
(IQR) and mean ± standard deviation (SD) were used to
report continuous variables, whereas frequencies with
percentages were used to describe categorical ones. One-
way ANOVA and Kruskal-Wallis k-samples were used to
compare means and medians between
three groups. Pearson’s Chi-Square test
and Mc-Nemar test were used to com-
pare the association between clinical
and pathologic variables. Two-tailed P
values less than 0.05 were considered
statistically significant. Statistical analy-
ses were conducted using SPSS® ver-
sion 21.0 for Macintosh® (IBM Corp,
Armonk, NY). 
RESULTS
Patient characteristics: Median age of
patients was 65.5 years (SD ± 6.6),
median total PSA serum level was 6.6
ng/ml (SD ± 4.1), median prostate
total volume was 51.1 cc (SD ± 26.7).
Thirty of 39 (76.9%) were biopsy-
naïve patients while 7/39 (17.9%) had
at least one previous negative random
TRUS-GB; 2/39 (5.1%) patients were
already diagnosed pCa on active sur-
veillance. Clinical, radiological and
pathological characteristics of the
entire population of the study are list-
ed in Table 1.
Detection rate All patient enrolled in
the study have been subjected both the
MRI-GB and the TRUS-GB. The major-
ity of suspected lesions identified with
mpMRI were located in the posterior
zone of the prostate (69% of cases). 
The mean number of bioptic cores
taken from patient was 1 in MRI-GB
series (range 1-2) and 12 in TRUS-GB
(range 12-14).As reported in table 5,
about overall detection rate (DR) of
patients who underwent “in-bore” MRI-
GB and TRUS-GB, in 23/39 (59%) men
PCa was diagnosed; as regards the MRI-
GB results related to the PI-RADS score,
biopsies of PI-RADS 3 lesions were pos-
itive in 5/18 cases (27.8%), while the
number of positive cases of PI-RADS 4
and 5 lesions was 7/11 (63.6%) and
6/10 (60%) respectively. Analyzing
the results of MRI-GB,  globally 17/39
(43.5%) patients presented a clinically
significant PCa (ISUP group ≥ 2), while
the DR for clinically significant PCa in
TRUS-GB was 15/39 patients (38.4%).
In the series of “biopsy naïve” patient we
observed 14/30 (46.7%) cases of PCa
detected by MRI-GB and 13/30 (43.3%)
cases in the series of TRUS-GB. In
patients with previous negative biopsies
we observed PCa in 2/7 (28.6%) cases
both in MRI-GB and TRUS-GB. In the
“active surveillance” group we detected
2/2 (100%) men with PCa in MRI-GB
series and 1/2 (50%) in TRUS-GB
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Table 1. 
Clinical and radiologic features of patients who underwent “in-bore” biopsy.
Overall Biopsy Previous Active p
(n = 39) näive negative biopsy surveillance value
(n = 30) (n = 7) (n = 2)
Age, years 65.5 ± 6.6 65.3 ± 6.8 66.6 ± 7.1 63.5 ± 2.1 0.8
Mean ± SD 
PSA, ng/ml 6.6 ± 4.1 11.7 ± 4.9 10.9 ± 7.4 6.2 ± 1 0.007
Mean ± SD 
PSA density, ng/ml/cc 0.14 ± 0.09 0.14 ± 0.09 0.15 ± 0.05 0.13 ± 0.04 0.95
Mean ± SD 
Prostate volume, cc 51.1 ± 26.7 46.7 ± 22.2 70.4 ± 38.1 52 ± 8.5 0.1
Mean ± SD 
Diameter mpMRI area, mm 11.9 ± 5.1 11.7 ± 4.9 13.1 ± 6.5 10 ± 5.7 0.7
Mean ± SD 
Area location mpMRI+, n (%)
Posterior 27 (69.2) 21 (70) 4 (57.1) 2 (100) 0.5
Anterior 12 (30.8) 9 (30) 3 (42.9) 0 (0)
PI-RADS-v2, n (%)
3/5 18 (46.2) 14 (46.7) 2 (28.6) 2 (100) 0.5
4/5 11 (28.2) 8 (26.7) 3 (42.9) 0 (0)
5/5 10 (25.6) 8 (26.7) 2 (28.6) 0 (0)
Table 3. 
“In-bore” biopsy results stratified according to PIRADS Score.
Overall PIRADS score PIRADS score  PIRADS score  p
3 4 5 value
Number of Pts, (%) 39 18 (46.2) 11 (28.2) 10 (25.6) -
Detection rate PCa, n (%) 18/39 (53.8) 5/18 (27.8) 7/11 (63.6) 6/10 (60) 0.3
Detection rate csPCa, n (%) 17/39 (43.5) 3/18 (16.7) 5/11 (45.5) 5/10 (50) 0.1
Detection rate csPCa/PCa, % 17/18 (94.4) 3/5 (60) 5/7 (71.4) 5/6 (83.3) 0.7
ISUP grade group, n (%)
Negative 21 (53.8) 13 (72.2) 4 (36.4) 4 (40) 0.1
1 1 (2.5) 1 (5.5) 0 (0) 0 (0)
2 10 (25.6) 3 (16.6) 5 (45.4) 2 (20)
3 4 (10.3) 1 (5.5) 1 (9.1) 2 (20)
4-5 3 (7.6) 0 (0) 1 (9.1) 2 (20)
Table 2. 
Overall and stratified according to clinical status “in-bore” results.
Overall Biopsy Previous Active p
näive negative biopsy surveillance value
Detection rate PCa, n (%) 18/ 39 (53.8) 14/ 30 (46.7) 2/7 (28.6) 2/ 2 (100) 0.2
Detection rate csPCa, n (%) 17/ 39 (43.5) 14/ 30 (46.6) 2 /7 (28.6) 1/ 2 (50) 0.1
csPCa/overall PCa rate, % 17/18 (94.4) 14/14 (100) 2 /7 (28.6) 1/ 2 (50) 0.2
ISUP grade group, n (%)
Negative 21 (53.8) 16 (53.3) 5 (71.4) 0 (0) 0.1
1 1 (2.5) 0 (0) 0 (0) 1 (50)
2 10 (25.6) 10 (33.3) 0 (0) 0 (0)
3 4 (10.3) 2 (6.6) 1 (14.2) 1 (50)
4-5 3 (7.6) 2 (6.6) 1 (14.2) 0 (0)
Table 4. 
Number of bioptic cores taken from patients who underwent in-bore 
and random biopsies.
Number of cores Overall Biopsy näive Previous negative Active surveillance  p
(n = 39) (n = 30) biopsy (n = 7) (n = 2) value
Total 13 (13-14) 13 (13-14) 13 (13-15) 13 (13-13) 0.5
In bore biopsy 1 (1-2) 1 (1-2) 1 (1-1) 1 (1-1) 0.5
Random biopsy 12 (12-12) 12 (12-12) 12 (12-14) 12 (12-12) 0.5
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series. The details of results are reported
in table 2-8. As far as the secondary
 endpoint is concerned, we have not
observed any complications related to
procedures.
DISCUSSION
TRUS-GB represents the “gold-standard”
technique of histological diagnosis of
prostate cancer. Aim of this study was
to investigate the real diagnostic accu-
racy of a novel prostate biopsy tech-
nique MRI guided compared to the
standard TRUS-guided biopsy (11).
During the recent years, there was an
increasing use of mpMRI in stadiation
of prostate cancer e in order to improve
quality of surgery during radical prosta-
tectomy (12). 
Other important application of mpMRI
is the guide to prostate biopsy in order
to improve PCa diagnosis with the aim
to refine PCa risk classification (13)
and, simultaneously, to overcome the
limitations of contemporary standard
TRUS-GB: low-risk patients could be
spared from biopsies reducing overde-
tection of low-risk cancer while a lower
number of cores could be required in
men with suspicious MRI findings
reducing also potential complications
related to the procedure and all the
consequence on quality of life (14-16).
Targeted MRI-GB has become an alter-
native approach to TRUS-GB and sever-
al MRI-GB methods have been pro-
posed for the diagnosis of PCa. In the
“cognitive” technique, TRUS-GB is
planned on the basis of MR images; in
spite of reduced costs, this method has
a long learning curve and the sampling
of suspicious lesions may not be guar-
anteed. The MRI-US “fusion” biopsy is
simply described as a way to align a
pre-registered MRI to an intraprocedur-
al US in order to identify and target sus-
pected lesions within the gland through
a dedicated hardware platform target-
ing areas found during mpMRI and not
clearly visible during US scan; the
advantages are the high reproducibility
and the real time feedback though
counterbalanced by the high up-front
cost of the device. The “in bore” tech-
nique consists in the execution of the
biopsies directly inside the MRI scanner
with dedicate non-magnetic biopsy
devices. Despite a longer operative time
and higher costs, this method has real-
time feedback in needle placement,
fewer sampled cores and a low likeli-
Table 5. 
Overall “detection rates” and “pathologic results” of patients who underwent 
“in-bore” biopsies and random biopsies.
Number of cores Overall (n = 39) In-bore biopsy Random biopsy  p value
Detection rate PCa, n (%) 23/39 (59) 18/39 (53.8) 18/39 (53.8) 0.9
Detection rate csPCa, n (%) 20/39 (51.3) 17/39 (43.5) 15/39 (38.4) 0.7
csPCa/PCa detection rate, % 20/23 (87) 17/18 (94.4) 15/18 (83.3) 0.8
ISUP grade group, n (%)
Negative 16 (41) 21 (53.8) 21 (53.8) 0.6
1 4 (10.3) 1 (2.5) 5 (12.8)
2 11 (28.2) 10 (25.6) 7 (17.9)
3 6 (15.4) 4 (10.3) 5 (12.8)
4-5 2 (5.1) 3 (7.6) 1 (2.6)
Table 6. 
Overall “detection rates” and “pathologic results” of biopsy näive patients who
underwent “in-bore” biopsies and Random biopsies.
Overall (n = 30) In-bore biopsy Random biopsy  p value
Detection rate PCa, n (%) 16/30 (75.4%) 14/30 (46.7) 1 /30 (43.3) 0.8
Detection rate csPCa, n (%) 15/30 (50%) 14/30 (46.6) 13/30 (43.3) 0.8
csPCa/PCa detection rate, % 15/16 (93.8%) 14/14 (100) 13/13 (100) 0.5
ISUP grade group, n (%)
Negative 14 (46.7) 16 (53.3) 17 (56.7) 0.7
1 1 (3.3) 0 (0) 0 (0)
2 9 (30) 10 (33.3) 8 (26.7)
3 5 (16.7) 2 (6.6) 4 (13.3)
4-5 1 (3.3) 2 (6.6) 1 (3.3)
Table 7. 
Overall “detection rates” and “pathologic results” of patients with previous
negative biopsies who underwent “in-bore” biopsies and random biopsies.
Overall (n = 7) In-bore biopsy Random biopsy  p value
Detection rate PCa, n (%) 4/7 (57.4) 2/7 (28.6) 2/7 (28.6) 0.3
Detection rate csPCa, n (%) 2/7 (42.9) 2/7 (28.6) 1/7 (14.2) 0.1
csPCa/PCa detection rate, % 2/4 (50) 2/7 (28.6) - -
ISUP grade group, n (%)
Negative 1 (14.3) 5 (71.4) 5 (71.2) 0.2
1 4 (57.1) 0 (0) 2 (28.6)
2 0 (0) 0 (0) 0 (0)
3 1 (14.3) 1 (14.2) 0 (0)
4-5 1 (14.3) 1 (14.2) 0 (0)
Table 8. 
Overall “detection rates” and “pathologic results” of patients in Active 
Surveillance who underwent “in-bore” biopsies and random biopsies.
Overall (n = 2) In bore biopsy Random biopsy  p value
Detection rate PCa, n (%) 2/2 (100 2/ 2 (100) 1/2 (50) 0.5
Detection rate csPCa, n (%) 2/2 (100) 1/ 2 (50) 1/2 (50) 1
csPCa/PCa detection rate, % 2/2 (100) 1/ 2 (50) 1 /1 (100) 0.5
ISUP grade group, n (%)
Negative 0 (0) 0 (0) 1 (50) 0.3
1 0 (0) 1 (50) 0 (0)
2 1 (50) 0 (0) 1 (50)
3 1 (50)) 1 (50) 0 (0)
4-5 0 (0) 0 (0) 0 (0)
hood of missed target. Therefore, the use of “in bore”
MRI-GB has the potential to reduce the sampling error
associated with unselective standard biopsy scheme by
providing better disease localization; moreover, accurate
risk stratification through improved cancer sampling
may impact therapeutic decision making (13, 17). In our
experience the overall detection rate of MRI-GB and
TRUS-GB are similar; in particular, in the series of MRI-
GB, we observed a slightly higher PCa diagnosis of clin-
ically significant disease (43.5% vs 33.3%), although this
result was not statistically significant. A recent systemat-
ic review showed that MRI-GB improved significant PCa
detection compared to standard TRUS-GB (relative sen-
sitivity 1.26, 95% CI 1.08-1.46) (18). In their prelimi-
nary experience with in-bore technique, Panebianco et al.
(19) showed a DR for the diagnosis of PCa of 80% and
90% of PCa cases had intermediate grade aggressiveness.
Whereas there was currently not enough evidence to rec-
ommend mpMRI before a first set of prostate biopsies
(2), the use of targeted biopsy often achieved significant-
ly higher cancer DR in the repeat biopsy setting. In
patients with prior negative biopsy, MRI-GB showed a
median DR of 42%, significantly higher than those
reported in repeating systematic biopsy (20). Our pre-
liminary experience in MRI-GB confirmed the feasibility
and the reproducibility of an “in-bore” strategy on a 1.5
T MR scanner using a 32-channel coil. Enghelard et al.
(21) reported a DR of 38% in 37 consecutive men with
elevated PSA levels and negative prostate biopsies under-
went a MRI-GB in a 1.5-T scanner in the supine position;
in similar but larger cohorts, Roethke et al. (22) and Hoeks
et al. (10) found a DR of 52% (52/100) and 41% (14/37),
respectively. In our cohort, analyzing the series of
patients with previous negative biopsies, the overall DR
of MRI-GB was higher than TRUS-GB (57.1% vs 28.6%),
particularly in the clinically significant disease (28.5% vs
14.2%). Our preliminary results highlighted the excel-
lent correlation between the PI-RADS score at mpMRI
and the ISUP grade groups in MRI-GB cores: this data
allows us to infer, on one hand, a high capability of the
mpMRI to predict the biological aggressiveness of neo-
plastic lesions and, on the other hand, the good per-
formance of the MRI-GB procedure. Moreover, the
mpMRI procedure with this setting and patients in the
prone position has been well tolerated and feasible to
perform. Given an initial learning curve, we believe that
the time needed for the procedure can be further
reduced optimizing the setting and the positioning of the
needle guide. Finally, Jung et al. (23) found that the rate
of positive MRI-GB resulted as a function of target size
and level of suspicious. It could be argued that obvious
that larger target with higher level of suspicious were
most likely to yield a positive biopsy; however, the
authors concluded that this finding could be helpful
when deciding whether to perform a MRI-GB. Engelhard
et al. (21) concluded that suspicious lesions with a diam-
eter > 10 mm could be successfully punctured using this
device. In spite of reliable feasibility and the preliminary
promising results with an acceptable DR, some limita-
tions of the present study have to be kept in mind. First,
the number of patients was small and, as a part of study
design, the patients analyzed were only men with posi-
tive findings at mpMRI: this selected patient population
from a single institution series may have a positive influ-
ence on the number of tumors detected; however, the
study was thought as an initial experience to compare
the MRI-GB technique and standard TRUS-GB in order
to evaluate its feasibility. Consequently, the preliminary
results are far from being meaningful and have to be
interpreted carefully. Second, the study lacks follow up
data and no prostate specimen histology can confirm the
results of a negative MRI-GB; further series with radical
prostatectomy specimen as reference standards are
required in order to corroborate the benefit of a MRI-GB
procedure. Finally, it is important to highlight that ini-
tially MRI-GB can represent a time-consuming and
expensive procedure but, as reported by other authors
(24), initial costs could be written off by reducing treat-
ment related costs and improving risk tumor evaluation
and quality of life preventing unnecessary radical treat-
ment of insignificant tumors.
CONCLUSIONS
MRI-GB represents a promising technique that may offer
some of these advantages compared to standard system-
atic TRUS-GB. Our preliminary experience in MRI-GB
resulted safe and feasible and represents a viable proce-
dure for the diagnosis and characterization of PCa espe-
cially in a subgroup of patient with clinically significant
disease. Further investigations are needed in order to
identify who should undergone prostate biopsy and the
technique that should be used with the aim of detecting
significant PCa and reducing the burden of biopsies.
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